ADVENTRX Pharmaceuticals to Present at the 20th Annual Bear Stearns Healthcare Conference

Tuesday, September 4, 2007 General News J E 4
SAN DIEGO, Sept. 4 ADVENTRX Pharmaceuticals,Inc. (Amex: ANX), a biopharmaceutical research and development company focusedon commercializing proprietary product candidates for the treatment of cancerand infectious diseases, announced today that Evan M. Levine, ADVENTRX's chiefexecutive officer is scheduled to present at the 20th Annual Bear StearnsHealthcare Conference on Monday, September 10th, 2007 at 8:30 a.m. EasternDaylight Time. The conference takes place in New York at the Grand Hyatthotel, September 10 - 11, 2007.

About ADVENTRX Pharmaceuticals

ADVENTRX Pharmaceuticals is a biopharmaceutical research and developmentcompany focused on commercializing proprietary product candidates for thetreatment of cancer and infectious diseases. The Company seeks to improve theperformance and safety of existing treatments by addressing significantproblems such as drug metabolism, bioavailability, excessive toxicity andtreatment resistance. More information can be found on the Company's web siteat

Forward Looking Statements

ADVENTRX cautions you that statements included in this press release thatare not a description of historical facts are forward-looking statements thatinvolve risks and assumptions that, if they materialize or do not prove to beaccurate, could cause ADVENTRX's results to differ materially from historicalresults or those expressed or implied by such forward-looking statements.These risks and uncertainties include, but are not limited to: the risk thatADVENTRX will be unable to raise sufficient capital to fund the projectsnecessary to meet its anticipated or stated goals and milestones; the abilityto timely enroll subjects in and the results of ADVENTRX's current andanticipated clinical trials; the potential for ADVENTRX's product candidatesto receive regulatory approval for one or more indications on a timely basisor at all, and the uncertain process of seeking regulatory approval; themarket potential for ADVENTRX's product candidates and ADVENTRX's ability tocompete in those markets; and other risks and uncertainties more fullydescribed in ADVENTRX's press releases and periodic filings with theSecurities and Exchange Commission. ADVENTRX's public filings with theSecurities and Exchange Commission are available at

You are cautioned not to place undue reliance on these forward-lookingstatements, which speak only as of the date when made. ADVENTRX does notintend to update any forward-looking statement, including as set forth in thispress release, to reflect events or circumstances arising after the date onwhich it was made.

SOURCE ADVENTRX Pharmaceuticals, Inc.


You May Also Like

View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
Exempla Healthcare Contracts For Talisman's Qualit...
New Survey Shows Americans are Still Concerned Abo...